Anti-Thymocyte Globulin · Thymoglobulin

What is Anti-Thymocyte Globulin?

Anti-Thymocyte Globulin is a purified gamma globulin obtained from animals immunized with human thymocytes. It contains antibodies against T-cell markers such as CD2, CD3, CD4, CD8 and CD25, leading to T-lymphocyte clearance and modulation of T-cell activity. It is studied in hematologic malignancies undergoing allogeneic stem cell transplantation and in kidney transplant recipients.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Thymoglobulin, antithymocyte globulin (rabbit)

Drug type

Plasma-derived product

Targets

CD2, CD3 (CD3E), CD4, CD8 (CD8A), CD25 (IL2RA), HLA-DR (HLA-DRA)

Mechanism

Immune activation, directed at CD2, CD3 (CD3E) and CD4

Pathways

T-cell clearance from circulation, T-cell activation modulation, T-cell homing and cytotoxic activity modulation

Therapy area

Oncology

Developer

Genzyme Corporation

In trials of

BMY, FATE

FDA status

Approved as Thymoglobulin (December 4, 1996), BLA103869 · FDA label

✅ FDA-approved uses

• Acute rejection in kidney transplant

From the indications section of the FDA label (version of Jun 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allogeneic Stem Cell TransplantationHematologic MalignanciesKidney Transplant RecipientsLiving-Donor Kidney Transplant

Other drugs acting on CD2 / CD3E / CD4 / CD8A / IL2RA / HLA-DRA

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Thymoglobulin (2026-06-24), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT04066114

Updated Oct 11, 2026.